2023
Immune dysfunction revealed by digital spatial profiling of immuno-oncology markers in progressive stages of renal cell carcinoma and in brain metastases
Schoenfeld D, Moutafi M, Martinez S, Djureinovic D, Merkin R, Adeniran A, Braun D, Signoretti S, Choueiri T, Parisi F, Hurwitz M, Rimm D, Wei W, Jilaveanu L, Kluger H. Immune dysfunction revealed by digital spatial profiling of immuno-oncology markers in progressive stages of renal cell carcinoma and in brain metastases. Journal For ImmunoTherapy Of Cancer 2023, 11: e007240. PMID: 37586773, PMCID: PMC10432651, DOI: 10.1136/jitc-2023-007240.Peer-Reviewed Original ResearchConceptsRenal cell carcinomaBrain metastasesPrimary tumorTumor microenvironmentDigital spatial profilingCell carcinomaActivation protein expressionInflammatory macrophage markersRCC brain metastasesInnate immune activatorsNormal kidney samplesProgressive stagesExtracranial metastasesTim-3Immune checkpointsImmune dysfunctionImmune activationRCC metastasisLonger survivalImmune activatorsMacrophage markersTreatment responseSeparate cohortTissue microarrayMetastatic samples
2020
Association between low estrogen receptor positive breast cancer and staining performance
Caruana D, Wei W, Martinez-Morilla S, Rimm DL, Reisenbichler ES. Association between low estrogen receptor positive breast cancer and staining performance. Npj Breast Cancer 2020, 6: 5. PMID: 32047851, PMCID: PMC7002746, DOI: 10.1038/s41523-020-0146-2.Peer-Reviewed Original ResearchER expressionER- tumorsBreast carcinomaTissue microarrayNormal epitheliumEstrogen receptor-positive breast cancerER casesReceptor-positive breast cancerControl patient populationER-positive tumorsEstrogen receptor expressionPositive breast cancerMean optical densityBackground epitheliumPositive tumorsControl cohortPatient populationControl tumorsReceptor expressionBenign epitheliumBreast cancerRare caseNormal ductsER stainingTumors